Pharmacotherapy for Vascular Cognitive Impairment

Area of Science:

• Neurology
• Gerontology
• Pharmacology

Background:

• Vascular cognitive impairment (VCI) is a leading cause of dementia, second only to Alzheimer's disease (AD).
• Stroke and cardiovascular risk factors are implicated in both AD and VCI, impacting cognitive function across the lifespan.
• Existing treatments for AD show limited and inconsistent benefits for VCI patients.

Purpose of the Study:

• To review the current evidence on pharmacological and non-pharmacological treatments for VCI.
• To identify gaps in research and suggest future directions for VCI management.

Main Methods:

• Literature review of clinical trials and studies on VCI treatments.
• Analysis of pharmacological agents, supplements, herbal therapies, and lifestyle interventions.
• Evaluation of evidence regarding cognitive, functional, and global benefits.

Main Results:

• Donepezil and galantamine show modest cognitive benefits in specific VCI subtypes (VaD, mixed dementia).
• Efficacy of other drugs (rivastigmine, memantine, nimodipine, piracetam) and supplements (citicoline, actovegin, huperzine A, vinpocetine) remains unclear.
• Non-drug therapies, including diet, exercise, and vascular risk factor control, are vital for VCI management.

Conclusions:

• Current pharmacological treatments for VCI offer limited and inconsistent benefits.
• Lifestyle modifications and vascular risk factor control are essential components of VCI management.
• Further high-quality clinical trials incorporating advanced imaging are necessary to establish effective VCI strategies.